'In 2018, a headline for an article in The Economist succinctly captured the paradox that is the global cancer industry: “Cancer is a Curse, but Also a Growth Market for Investors.” Cancer’s definitely a curse, that’s for sure, but cancer drugs, with chemotherapy drugs taking up the lion’s share, are on pace to become a $200 billion industry in the next few years, up from $100 billion in 2015.
This is serious growth, and forecasts see global cancer rates exploding in coming years. An investor’s dream, but the reality of cancer treatment is that patients are often unaware of the mortal risks of cancer drugs, especially chemotherapy. In 2017, we reported on a study from the Albert Einstein College of Medicine of Yeshiva University in New York, indicating that chemotherapy often causes cancer to become more aggressive, and can cause tumors to spread.
Many are given chemotherapy before surgery, but the new research suggests that, although it shrinks tumours in the short term, it could trigger the spread of cancer cells around the body.
It is thought the toxic medication switches on a repair mechanism in the body which ultimately allows tumours to grow back stronger. It also increases the number of ‘doorways’ on blood vessels which allow cancer to spread throughout the body. [Source]
This notion is reflected in data in another study, from Public Health England and Cancer Research UK, which looked at 30-day mortality post systemic anticancer treatments (SACT) to determine benchmarks for surviving SACT. The results highlight a critical problem with the cancer industry, the treatment often kills the patient long before the cancer may have.'
Read more: Study Reveals Many Cancer Patients Are Killed By Chemotherapy, Not Cancer